Drugs / 2217LS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04863287 | Feb 2021 → Aug 2022 | Lyme disease | MassBiologics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-31 | Tonix Pharmaceuticals, Inc. | Results Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 tonixpharma.com ↗
announced Phase 1 data of TNX-4800 (formerly known as mAb 2217LS) 1,2 was presented by Mark S. Klempner, MD, professor of medicine at UMass Chan Medical School, an inventor of TNX-4800 and principal investigator of the study |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-31 | Tonix Pharmaceuticals, Inc. | Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 tonixpharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2217LS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04863287 ↗ |
| Modality | Monoclonal antibody | “Fully Human Monoclonal Antibody” NCT04863287 ↗ |
| Route | Subcutaneous | “a subcutaneous (SC [under the skin]) injection of 2217LS” NCT04863287 ↗ |